Risk of Fixed Drug Eruption with Piroxicam (26 Sep 2022)
Risk of Fixed Drug Eruption with Piroxicam (26 Sep 2022)
Risk of Fixed Drug Eruption with Piroxicam (26 Sep 2022)
On 26 Sep 2022, PvPI identified the Risk of Fixed Drug Eruption with the use of Piroxicam
The preliminary analysis of Adverse Drug Reaction (ADR) from the PvPI database reveals that the following suspected drug (Piroxicam) is associated with the Fixed Drug Eruption
Piroxicam is in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, cervical spondylitis and other musculoskeletal disorder.
Anti-inflammatory agent- Indicated in the treatment of rheumatoid arthritis, ankylosing spondylitis and other musculoskeletal disorders.
Indicated in the treatment of musculoskeletal disorders, acute gout, pain after operative intervention following acute trauma and in primary dysmenorrhoea (12 years age or older)
Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App “ADR PvPI” and PvPI Helpline No. 1800-180-3024.
For more information, Login Indian Pharmacopoeia Commission
Find Remdesivir Safety profile
